



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

- (43) Date of publication:  
28.02.2001 Bulletin 2001/09
- (51) Int. Cl.<sup>7</sup>: **A61K 31/715, A61K 9/08**
- (21) Application number: 99916742.2
- (86) International application number:  
**PCT/CN99/00055**
- (22) Date of filing: **16.04.1999**
- (87) International publication number:  
**WO 99/59602 (25.11.1999 Gazette 1999/47)**

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

(30) Priority: **15.05.1998 CN 98108902**

(71) Applicant: **Zhao, Chaoying**  
Shanghai 200433 (CN)

(72) Inventor: **Zhao, Chaoying**  
Shanghai 200433 (CN)

(74) Representative: **Eisy, David et al**  
Withers & Rogers,  
Goldings House,  
2 Hays Lane  
London SE1 2HW (GB)

(54) **NOVEL PHARMACEUTICAL COMPOSITION FOR USE IN EMERGENCY TREATMENT AND PREPARATION METHOD THEREOF**

(57) The present invention relates to a pharmaceutical composition and the method for the preparation thereof. The composition comprises 1.5~ 6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, and the like, and 3~ 18% (w/v) of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, polyvinyl-pyrrolidone, gelatin derivatives, and the like as well as the remainder of conventional injections, as long as sodium chloride is not less than 1.5% (w/v). The pharmaceutical composition of the present invention is used to treat and save the wounded and patients, as well as to treat shock, its advantages include safe and convenient use, rapid and good curative effect, long time maintenance, extensive uses and the like.

RFST AVAILABLE COPY

**Description**

[0001] The present invention relates to a novel pharmaceutical composition for treating and saving the wounded, and to a method for the preparation thereof.

5 [0002] Nowadays blood transfusion and fluid infusion are the important measures to treat and save the wounded, especially the traumatic shock. Usually, the principle of transfusion is "to infuse component the patient is deficient in, to supply how much the patient needs". For example, when the patient mainly lost his blood, he should be transfused with blood, even though sometimes the patient needs to be transfused with blood from normal individuals. When the patient mainly lost plasma, plasma or plasma volume expander should be transfused to him; when the patient mainly lost inter-  
10 cellular fluid, physiological saline should be infused. In fact, the treating and saving measures of formulating physiological solutions on the basis of normal composition of body, or transfusing with blood from normal individuals to the patient with evident physiopathological changes is to treat the organism as mechanical device, therefore these measures often have following disadvantages:

15 (1) Blood transfusion: In general, the volume of blood transfusion closes to or exceeds the volume of blood lost. If a big amount of blood is required, the blood source will be difficult, the cost is expensive. The preparation and storage need certain conditions. In addition, before transfusion, some time should be taken for blood typing and cross match tests, and only the substitutes could be used for the individuals with rare blood types. Blood transfusion could result in production of anti-platelet antibodies and anti-leucocyte antibodies, as well as various hematogenous  
20 infectious diseases, for example, AIDS, hepatitis B, hepatitis C. etc.

25 (2) Albumin infusion: There is a great demand, a great expense difficult source, complicated preparation method and certain requirements for the method storage. After albumin infusion, it could effuse through capillaries, and couldn't be reabsorbed into vessel. Therefore interstitial edema will occur, and might result in pulmonary edema, renal failure, and cardiac insufficiency, by contrast enhance the mortality. Albumin infusion could result in evident decrease of  $\alpha_1$ ,  $\alpha_2$ ,  $\beta$ ,  $\gamma$ -globulins and fibrinogen, cause reduction of immunity, and affect function of blood coagulation.

30 (3) Infusion of fluorocarbon as plasma substitute: It requires a large amount of the substitute and simultaneous inhalation of oxygen with high component pressure. Otherwise the demand of the organism is not met. The fluorocarbon as plasma substitute should be preserved in low temperature, and its transport is not convenient. For example, thirty minutes before infusion the patient should be injected with 10 mg of dexamethasone. The frozen injection for infusion should be thawed. Thus, the procedures are complicated. After infusion, the observation should be continued for 5 -- 10min. The infusion of fluorocarbon as plasma substitute could induce adverse reactions, such as anaphylaxis, hypotension, thrombocytopenia, hepatosplenomegaly, reduction of immunity, and abnormality of fibrinolysis system.

35 (4) Infusion of balanced buffers, Its amount infused should be three times more than the volume of blood lost to maintain the blood pressure. 60--80% the solution infused could effuse out of the blood vessel, which results in tissue edema (for example, cerebral edema, pulmonary edema) and renal insufficiency, it could cause the difficulty for sequential therapy.

40 (5) Infusion of physiological saline. Its amount infused should also be three times more than the volume of blood lost. Its efficacy is poorer than balanced buffers, and its adverse effects are more significant.

[0003] To solve the problems in blood transfusion and infusion, the skilled in the art had studied anti-shock therapy with hypertonic sodium chloride solution. For example, 7. 5% (w/v) NaCl solution suggested by Velasco. But the hypertonic NaCl solution has some toxicity to the organism.

45 [0004] Most investigators have proposed intravenous injection of hypertonic NaCl solution for anti-shock therapy, but it usually leads to obvious complications, such as hypotension, rupture of blood cells induced by extra hypertonic solution, cardiac insufficiency, decreased renal function and disorders of nervous system.

[0005] Thus, it can be showed that there is a demand for novel anti-shock drugs to reverse the physiopathological condition of shock, in order to obtain time for sequential therapy after the emergency treatment, and to create opportunity with improved effect of treating and saving the wounded and patients, and with increased survival rate.

50 [0006] An object of the present invention is to provide a pharmaceutical composition with convenient source, less dosage, rapid and better efficacy, less side effects, wider uses, and without restriction by blood type as well as without special storage condition.

[0007] Another object of the present invention is to provide the method for the preparation of the said pharmaceutical composition.

55 [0008] The present invention proposes a new concept of liquid therapy for shock, based on three aspects of thinking. The first aspect in connection with the present unreasonable dosage regimen, following principle is adopted: "to infuse what component the patient needs, then to infuse how much the patient needs". Based on the physiopathological

status of the patient with shock, there is a prior demand for the compound solution containing hypertonic sodium ion (or combination of various crystals, or combination of various crystals and various colloids, etc.) to preliminarily improve micro-circulation, tissue perfusion, and hemodynamics immediately. Then in the light of practical demand the isosmotic solution or proper hypoosmotic solution or whole blood or concentrated red blood cell suspension is administered, in order to permit the latter infused solution better action when the patient's condition has improved preliminarily by the earlier hypertonic solution, and to remit over-dehydration of some cells caused possibly by the hypertonic solution infused earlier. The second aspect, in connection with the present unreasonable ratio of colloids and crystals in the transfusion for patient with shock prepared on basis of their normal physiological concentrations, in view of the fact that the property and volume-expanding ability of artificial colloids are different from albumin in blood, it is considered that the transfusion with suitable ratio of colloids and crystals, instead of human normal physiological proportion, should be administered on basis of the physiopathological status of patients. Thus medicine administration according to indications could reduce the dosage, increase the efficacy, and decrease the complications. The third aspect, in connection with a lot of inadequacy in the present anti-shock experimental studies (such as animal model, reasonable concentration and infusion rate of hyperosmotic solutions), a great number of experimental studies have been conducted, and met with success.

[0009] Based on the above three aspects of thinking form the theoretical researches and the clinical experiences, the particular embodiments of the present invention have been completed through the animal experiments and the clinical practice.

[0010] The present invention is achieved through the following embodiments. A pharmaceutical composition comprising 1.5-6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, calcium lactate, sodium lactate, sodium acetate and Tris (Hydroxy methyl) aminomethane; and 3--18%(w/v) of one or more substances selected from hydroxyethylstarch, dextran, carboxy methylstarch, polyvinyl-pyrrolidone (PVP), gelatin derivatives, condensed glucose, glucose, fructose, lactose, glycerin, xylitol, sodium alginate, N-2-hydroxypropylacrylamide, ethylene epoxide--polypropylene glycol, pectin, mannitol, and penta hydroxyethylstarch (Pentastarch) as well as the remainder of conventional injections, as long as sodium chloride is not less than 1.5% (w/v), and the concentration of sodium ion is not more than that of in 6.9% (w/v) sodium chloride solution or equivalent.

[0011] The preferred composition of the present invention consisting of  $4.2 \pm 0.2$  g sodium chloride and  $7.6 \pm 0.6$  g hydroxyethylstarch per 100ml.

[0012] In the composition, the said hydroxyethylstarch contains at least 10% hydroxyethylstarch with molecular weight of 25,000--45,000.

[0013] The said dextran has molecular weight of 40,000--230,000, carboxymethylstarch has molecular weight of 30,000--80,000, PVP has molecular weight of 5,000--700,000, condensed glucose has molecular weight of 8,000--12,000; sodium alginate has molecular weight of 20,000--26,000; pectin has molecular weight of 20,000--40,000; pentahydroxyethylstarch is the product of DuPont Company (Pentastarch) with molecular weight of 264,000.

[0014] The said gelatin derivatives have molecular weight of 20,000-35,000, and are selected from urea-conjugated gelatin, modified liquid gelatin, oxidized polygelatin and degraded gelatin poly-peptide.

[0015] Conventional injections are selected from water for injection, physiological saline, balanced buffers, glucose solution, sodium lactate solution, sodium acetate solution, Tris solution, and glucose and sodium chloride solution.

[0016] The composition of the present invention is prepared as following procedure: dissolving 3--18g of total amount of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, PVP, gelatin derivatives, condensed glucose, glucose, fructose, lactose, glycerin, xylitol, sodium alginate, N-2-hydroxypropylacrylamide, ethylene epoxide--polypropylene glycol, pectin, mannitol, and pentahydroxyethylstarch in 100 ml of total volume of one injection or mixture of several injections selected from water for injection, physiological saline, balanced buffers, glucose solution, sodium lactate solution, sodium acetate solution, Tris solution, and glucose and sodium chloride solution; then adding 1.5g sodium chloride and 0--5.4g of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, calcium lactate, sodium lactate, sodium acetate, and Tris; with the proportion described above, then mixing, and dissolving, to obtain the composition of the present invention.

[0017] The preferred technical embodiments are as follows: (i) preparation of hydroxyethylstarch: According to the proportion of 1:0.8-0.875:0.04-0.042 (w/v/v), corn starch or sorghum starch, and 95% ethanol, and 35--38% hydrochloric acid are mixed, the temperature is raised to 65--80 °C for hydrolysis of starch, 16% sodium hydroxide solution is added in proportion of 0.6--0.7:1 (v/w) of stated solution versus starch. Then ethylene epoxide is added in proportion of 0.35--0.5:1 (w/w) of ethylene epoxide versus starch, then the mixture is heated to 65--75 °C to cause starch hydroxyethylation. (ii) Formulation of the composition: Appropriate volume of water is added, to prepare  $7.6 \pm 0.6$  (w/v) hydroxyethylstarch solution. Suitable amount of activated charcoal is added to discolor the solution through adsorption. After filtration, the pH is adjusted to 5.5--7, and the total of  $4 \pm 0.2$  g of sodium chloride is added, suitable amount of activated charcoal is added again for adsorption and discolor action. After filtrated through 0.8 μm micro-porous filter,

the preferred composition of the present invention is obtained.

[0018] The present invention is further illustrated in detail by the following examples.

Preparative example.

5 Preparation of hydroxyethylstarch.

[0019] 100g Corn or sorghum starch are mixed with 87ml of 95% ethanol and 4. 2 ml of 35% hydrochloric acid. The temperature is raised to 70°C to hydrolyze starch then 60ml at 16% sodium hydroxide solution is added, then 45g epox-  
10 yethane is added, and the mixture is heated to 70 °C to complete hydroxyethylation of starch. According to the formula and preparative method described above hydroxyethylstarch with molecular weight of 25, 000--45, 000 is obtained.

Example 1.

15 Prepare according to the following proportion:

[0020]

hydroxyethylstarch	7.6g
sodium chloride	4.2g
water for in injection	added to 100ml

25

[0021] 7. 6g hydroxyethylstarch are dissolved in 100 ml of water for injection. 0. 5g of activated charcoal is added, and the mixture is heated at 90°C for 15 min under stirring. After filtration through asbestos plate filter, 4. 2g sodium chloride (purity pharmaceuticals use) are added, and dissolved with stirring. 0.5g activated charcoal is added, and the  
30 mixture is heated at 90°C for 10 min under stirring. After filtration through asbestos plate filter and 0. 8μm micro-porous filter, resulted filtrate is transferred into 250ml or 500-ml glass or plastic bottles (bags), after sealing the bottles or bags are 1.05 kg/cm<sup>2</sup> and 121-123 °C for 15--30min for sterilization, to obtain the pharmaceutical composition of the present invention;

35 Example 2.

Prepare according to the following proportion:

[0022]

dextran	9g
hydroxyethylstarch	3g
sodium chloride	1.5g
sodium bicarbonate	3.4g
physiological saline	added to 100ml

40

45 [0023] Above--mentioned dextran (produced by Shanghai Glucose Factory), hydroxyethylstarch (prepared according to preparative example) are dissolved in physiological saline, and adsorbed and discolored with activated according to the method stated in Example 1. Then above--mentioned sodium chloride, sodium bicarbonate, are added in turn,  
50 and dissolved with stirring. There after the obtained solution is discolored, filtered, sterilized and filled, to obtain the pharmaceutical composition of the present invention.

Example 3.

Prepare according to the following proportion:

5 [0024]

10	polyvinyl-pyrrolidone (PVP) (produced by Bayer)	12g
15	sodium chloride	2g
20	sodium acetate	4g
25	10% glucose solution	added to 100ml

[0025] According to the method described in Example 2 except that dextran and hydroxyethylstarch is replaced by PVP, sodium bicarbonate is replaced with sodium acetate, and physiological saline is replaced with glucose solution, the composition of the present invention is obtained.

Example 4.

Prepare according to the following proportion:

25 [0026]

30	sodium alginate (produced by Nanning Pharmaceutical Factory, Guangxi)	18g
35	sodium chloride	1.5g
40	water for injection,	added to 100ml

[0027] According to the method described in Example 1 to prepare the above--mentioned formulation, thus obtaining the pharmaceutical composition of the present invention.

Example 5.

Prepare according to the following proportion:

40 [0028]

45	pectin (produced by PLA No. 185 Hospital)	3g
50	Pentahydroxyethylstarch (produced by DuPont Company)	4g
	sodium chloride	4g
	mannitol	7g
	2% sodium lactate lution	added to 100ml

[0029] According to the method described in Example 1, pectin Pentahydroxyethylstarch and mannitol are dissolved in sodium lactate solution, then sodium chloride is added and dissolved.

## Example 6.

Prepare according to the following proportion:

5 [0030]

10	condensed glucose (produced by southwest No. 5 Pharmaceutical Factory Chongqing) N-2-hydroxy propyl acrylamide sodium chloride water for injection	7g 2g 4.4g added to 100ml
----	---	------------------------------------

15 [0031] Using the method in Example 1, the pharmaceutical composition of the present invention is prepared according to the above mentioned formula.

## Example 7.

20 Prepare according to the following proportion:

[0032]

25	fructose (produced by Shanghai No. 2 Reagent Factory) xylitol (produced by Liaoyang organic Chemical Plant) sodium chloride water for injection	5g 4g 4.8g added to 100ml
----	--	------------------------------------

30 [0033] Using the method in Example 1, the pharmaceutical composition of the present invention is prepared according to the above--mentioned formula.

## Example 8.

35 Prepare according to the following proportion:

40 [0034]

45	glycerin lactose (produced by Shanghai No. 2 chemistry Reagent Factory) sodium chloride water for injection	2g 5g 6g added to 100ml
----	--	----------------------------------

50 [0035] Using the method in Example 1, the pharmaceutical composition of the present invention is prepared according to the above-mentioned formula.

55 Test 1: Animal Experiment

[0036] From adult healthy hybrid dogs, regardless of sex, under local anesthesia, isolate femoral artery and femoral vein, then insert catheters respectively.

[0037] The arterial duct is connected to CF-II model monitor of cardiovascular function [Shanghai approval document number: Hu--Yao- Qi--Jian (Zhun)--97--221103] to monitor cardiovascular status. Bleed these dogs to monitor cardiovascular status. Bleed these dogs to average arterial pressure (MAP) of 40--50 mmHg for a period of about 15 min. Maintain this blood pressure level for 1 hour, then infuse the product prepared in Example 1 at the dose of 8 ml/kg.

5 [0038] Monitor the cardiovascular function and urine volume over 4 hours after infusion. In the following tables, the blood pressure and other indexes are expressed as percentage of their basal levels respectively, the unit of urine volume is ml/kg body weight/h.

10

15

20

25

30

35

40

45

50

55

Table 1  
Comparison between the composition of the invention and whole blood in equal volume of recovery of  
Cardiovascular function in dogs with shock. [unit: % compared with respective basal level]

		after transfusion			
		30min	1h	2h	3h
Systolic pressure	composition of the invention	75±4	76±4	77±4	78±5
	equal volume of whole blood	67±5 (p<0.01)	69±6 (p<0.01)	73±4 (p<0.05)	73±4 (p<0.05)
diastolic pressure	composition of the invention	77±5	79±5	81±4 (p<0.05)	81±5 (p<0.05)
	equal volume of whole blood	69±6 (p<0.01)	73±8 (p<0.05)	76±7 (p<0.05)	76±7 (p<0.05)
average arterial composition	of the invention pressure	76±4	78±4	79±4	80±5
	equal volume of whole blood	68±5 (p<0.01)	71±6 (p<0.01)	74±4 (p<0.05)	75±4 (p<0.05)
cardiac contractility	composition of the invention	77±5	79±5	81±4 (p<0.05)	81±4 (p<0.05)
	equal volume of whole blood	69±6	73±8	76±7	76±8
cardiac output	composition of the invention	105±13	106±14	103±14 (p<0.01)	106±12 (p<0.01)
	equal volume of whole blood	89±10 (p<0.05)	83±18 (p<0.05)	83±15 (p<0.01)	88±23 (p<0.01)
end-diastolic volume	composition of the invention	82±4	82±3	83±4 (p<0.05)	84±3 (p<0.05)
	equal volume of whole blood	78±7 (p<0.05)	78±9 (p<0.05)	80±7	82±8

Table 2

Comparison between composition of the invention and equal volume of whole blood For urine volume in restoration stage in shocked dogs [unit: ml/kg/h]				
	after transfusion			
	1h	2h	3h	4h
Composition of the invention	2.23 ± 1.03	0.94 ± 0.22	0.95 ± 0.29	1.00 ± 0.30
equal volume of whole blood	0.33 ± 0.21 (p<0.01)	0.27 ± 0.16 (p<0.01)	0.73 ± 0.41	0.61 ± 0.25 (p<0.05)

[0039] The composition of the Example 1 of the invention was administered to 48 patients in Hefei No. 105 Hospital, Anhui province. The total effective rate was 100%. Most patients, had the blood pressure raised, urine volume increased, and the limbs became warm during transfusion. Several patients whom the conventional drugs couldn't already reverse, the composition of the Example 1 of the invention begin to play its role 5-- 10minutes after infusion. The circulatory function of patients has recovered basically, (and there were no obvious clinical complications).

### Test 3. Experiment of acute toxicity

[0040] when dogs were given at 2.5 times the dosage for human, no adverse effects have been showed. At 5 times the recommended dosage, salivation and vomiting were seen in the dogs. At 3. 75 times the recommended dosage vomiting was seen without salivation in the dogs. All the above administered dogs survived more than 45 days. At 7. 5 times the recommended dosage the death occurred in the administered dogs. focal hemorrhage was seen in the lungs as target organs.

[0041] The composition of the present invention could be infused through vein at the dose of 8 ml of the composition of the present invention per kg body weight. It could be used directly in treating and saving the patients with shock, combined injuries or hematorrhea etc in order, to reverse the physio-pathological status of patients and to obtain time for sequential treatment.

[0042] As compared with the prior art, the pharmaceutical composition, of this invention has the following prominent features and improvement:

- Greatly decreased volume of transfusion: In general, the dose for most patients is 500 ml or less than 500 ml. Even if the patients suffered from lethal hematorrhea, to infuse only 1/4 to 1/6 of volume of lost blood is enough. Thus, it could obviously decrease the incidence rate of tissue edema or overload of heart.
- Rapid curative effect just during 5-- 10 minutes after infusion, the hemodynamics has been improved significantly.
- Good efficacy. As Test 1 showed the composition of the invention had better efficacy than that of equal volume of fresh whole blood. Moreover, although the composition of the invention has no oxygen- carrying action, but it could improve micro-circulation and general status to decrease oxygen consumption and to increase oxygen transport. Thus at least 50% of blood transfused could be saved, it could mitigate the contradiction with short supply of blood, decrease the complications induced by blood transfusion, and reduce obviously the economic burden for the patients.
- Maintain once of efficacy for long time. As Test 1 showed, after infusion of the composition of the invention, the improvement of hemodynamics and general condition could be maintained more than 3-4 hours, even if all other infusion and drugs were not administered.
- Unnecessary special condition for storage: The composition could be stored at room temperature, simply used infused intravenously or intraosseously and conveniently transported, without special devices and special vehicles.
- Unnecessary blood typing and cross match tests: It is suitable for individual with any blood type. Thus the valuable time could be gained to rescue the wounded and patients.
- Wider uses: It could widely be used in the treatment of patients with shock of various types, brain trauma burn, combined injuries, cardiogenic shock induced by myocardial infarction of right ventricle, hypotension induced by hemodialysis, biliary pancreatitis, cardiovascular intoxication induced by narcotic, hepatic echinococcosis, and patients under operation.
- Change of administration model: The composition of the invention could be infused drop by drop intravenously,

instead of pushing so it could be conveniently used with less complications.

[0043] In general, as compared with prior therapy, the composition of the present invention possesses unique benefit and theoretical innovation, for treating and saving the wounded and patients, so it is active significance.

## 5 Claims

1. A pharmaceutical composition comprising 1.5--6.9 % (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, calcium lactate, sodium lactate, sodium acetate and Tris (Hydroxy methyl) aminomethane, and 3~18 % (w/v) of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, polyvinyl-pyrrolidone (PVP), gelatin derivatives, condensed glucose, glucose, fructose, lactose, glycerin, xylitol, sodium, alginate, N--2-hydroxypropylacrylamide, ethylene epoxide-polypropylene glycol, pectin, mannitol, and pentahydroxyethylstarch; as well as the remainder of conventional injections, as long as sodium chloride is not less than 1.5 % (w/v), and the concentration of sodium ion is not more than that of 6.9 % (w/v) sodium chloride solution or equivalent.
2. The pharmaceutical composition of Claim 1, wherein the composition contains  $4.2 \pm 0.2$ g sodium chloride and  $7.6 \pm 0.6$ g hydroxyethylstarch per 100 ml.
3. The pharmaceutical composition of Claim 1 or 2, wherein the conventional injections are selected from water for injection, physiological saline, balanced buffers, glucose solution, sodium lactate solution, sodium acetate solution, Tris solution, and glucose and sodium chloride solution.,
4. The pharmaceutical composition of Claim 1 or 2, wherein hydroxyethylstarch contains at least 10% hydroxyethylstarch with molecular weight of 25, 000--45, 000.
5. The pharmaceutical composition of Claim 1, wherein gelatin derivatives have, molecular weight of 20, 000~35, 000, and are selected from urea-conjugated gelatin, modified liquid gelatin, oxidized polygelatin and degraded gelatin polypeptide.
6. The pharmaceutical composition of Claim 1, wherein dextran has molecular weight of 40, 000--230, 000; carboxymethylstarch has molecular weight of 30, 000--80, 000, PVP has molecular weight of 5, 000--700, 000, condensed glucose has molecular weight of 8, 000~ 12, 000, sodium alginate has molecular weight of 20, 000--26, 000, pectin has molecular weight of 20, 000~40, 000; pentahydroxyethylstarch has molecular weight of 264, 000.
7. A method for preparing the pharmaceutical composition of Claim 1, comprising: dissolving 3--18g of one or more substances selected from hydroxyethylstarch, dextran, carboxymethylstarch, PVP, gelatin derivatives, condensed glucose, glucose, fructose, lactose, glycerin, xylitol, sodium alginate, N--2-hydroxypropylacrylamide, ethylene epoxide-polypropylene glycol, pectin, mannitol, and pentahydroxyethylstarch, in total of 100 ml of one injection or mixture of several injections selected from water for injection, physiological saline, balanced buffers, glucose solution, sodium lactate solution, sodium acetate solution, Tris solution, and glucose and sodium chloride solution; the adding 1.5g sodium chloride and 0--5.4g of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, calcium lactate, sodium acetate, and Tris with the proportion described above, then mixing, dissolving, to obtain the composition of the present invention.

50

55

<b>INTERNATIONAL SEARCH REPORT</b>		<b>International application No.</b> <b>PCT/CN99/00055</b>
<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC (6): A61K 31/715 , 9/08		
According to International Patent Classification(IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched(classification system followed by classification symbols)		
IPC (6): A61K 31/70, 31/715, 33/14, 9/08		
Documentation searched other than minimum documentation to the extent that such documents are included in the field searched Chinese Patent Documentation		
Electronic data base consulted during the international search(name of data base and, where practicable, search terms used) WPI(Derwent), CNPAT(CN), JOPAL(JP), EPDOC(EPO)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
X	CN1156587(SUN Xuguang)13 • August 1997(13.08.97), Example2	1,3,7
A	CN1195527A(BI Yanwen)14 • October 1998(14.10.98), Full text	1-7
A	CN1042474A(JINAN MILITARY REGION PHARMACEUTICAL RESEARCH CENTRE)30 • May 1990(30.05.90), Claims	1-7
A	JP4069341(OTSUKA SEIYAKU KOGYO KK)04 • March 1992 (04.03.92), Abstract	1-7
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		<input type="checkbox"/> See patent family annex.
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason(s) specified</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
Date of the actual completion of the international search  12 March 1998 (12.03.98)	Date of mailing of the international search report  27 MAY 1999 (27.05.99)	
Name and mailing address of the ISA/ The Chinese Patent Office 6, Xitucheng Road, Haidian District, Beijing, 100088, China Facsimile No. 86-10-62019451	Authorized officer  ZHAO Xiyuan Telephone No. 01062093891 	

Form PCT/ISA/210(second sheet)(July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.